Impairment of hepatic drug oxidation by propoxyphene

D. R. Abernethy, D. J. Greenblatt, K. Steel, R. I. Shader

Research output: Contribution to journalArticlepeer-review

Abstract

We report a doxepin-treated patient whose doxepin plasma levels were monitored before and during propoxyphene therapy. The pharmacokinetic interaction was further assessed by a study of antipyrine metabolism, used as a marker for drug oxidation, before and during propoxyphene treatment in healthy subjects. Impairment of antipyrine metabolism, used as a qualitative marker, provided evidence that increased doxepin and desmethyldoxepin levels shown in the elderly patient were the result of impaired oxidative drug metabolism. Propoxephene may inhibit human in-vivo oxidative drug metabolism in other cases as well, and this may explain in part the frequent morbidity and mortality seen when propoxyphene is concurrently taken with other oxidatively metabolized drugs.

Original languageEnglish (US)
Pages (from-to)223-224
Number of pages2
JournalAnnals of internal medicine
Volume97
Issue number2
DOIs
StatePublished - 1982

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Impairment of hepatic drug oxidation by propoxyphene'. Together they form a unique fingerprint.

Cite this